[Metabolic disturbances associated with HAART].
HAART changed natural course of infection with HIV, reduced the morbidity and mortality of AIDS patients. The lipodystrophy syndrome is long-term complication of antiretroviral therapy characterized by changes in body fat redistribution changes and metabolic abnormalities: insulin resistance, hyperglycemia, diabetes type 2, hypertriglyceridemia and hyperlipidemia. The pathogenesis is multifactorial due to interplay of viral, host and drug related factors. The HIV protease inhibitors and NRTI may play a pathogenic role. The potential risk factors include treatment with PIs and NTRIs, increasing age, gender and genetic predispositions.
Olczak
Anita
A
Klinika i Katedra Chorób Zakaźnych i Hepatologii CM UMK. mpawlowska@cm.umk.pl
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D008060:Lipodystrophy / Q000139:chemically induced; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000378:metabolism; D024821:Metabolic Syndrome / Q000139:chemically induced; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D012307:Risk Factors
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors